FINARO
11.3.2022 14:32:08 CET | Business Wire | Pressemeddelelse
Finaro (tidligere Credorax) , en global betalingsudbyder og Europæisk bank, der styrker international handel gennem teknologiske og enkle betalingsløsninger, har i dag offentliggjort, at de har indgået en aftale med Shift4 omkring salget af Finaro til en værdi af 575 millioner USD. Det kombinerede tilbud, fra begge virksomheder, skaber en positiv synergi af et globalt betalingsnetværk med en betydelig POS og eCommerce platform, på tværs af en bred vifte af vertikaler, der servicerer store og komplekse virksomheder med unikke løsninger. Sammen vil Finaro og Shift4 være bedre i stand til at forsyne virksomheder med globale betalingsløsninger gennem flere kanaler, og stå side om side med nogle af de største aktører i betalingsbranchen, heriblandt Adyen, Nuvei og WorldPay.
“Dette køb understreger vores offensive bestræbelser på, at levere en unified commerce oplevelse overalt i verden. Denne handel viser tydeligt vores evne til at støtte eksisterende transformerende og globale kunder, såsom SpaceX Starlink & St. Jude Children’s Research Hospital,” fortæller Shift4s CEO Jared Isaacman.
Finaro vil levere den globale infrastruktur og den nødvendige banebrydende teknologi, for at føre Shift4s internationale ambitioner ud i livet om at levere en unified commerce løsning. Ved at integrere Finaros kapaciteter, vil Shift4 være i stand til at udvide virksomhedens nuværende serviceydelser overalt i verden, inklusiv dens næste generation af SkyTab POS-løsning, Shift4Shop e-handelsplatform og VenueNext stadiontilbud. Shift4 har også mere end 425 softwareintegrationer og over 200.000 merchants, hvoraf mange har en multinational tilstedeværelse, og giver øjeblikkelige internationale muligheder, som der nu kan åbnes for som et resultat af denne nyerhvervelse.
“Denne erhvervelse understreger, at vi har opnået, hvad vi har sat os for at opnå – at opbygge pålidelige betalingsbehandlingskapaciteter, som i sandhed er uden grænser, både hvad angår tilgængelighed og størrelse. At kunne anvende denne teknologi til SpaceXs Starlink-program, og andre der er tilsvarende i størrelsen, samtidig med også at kunne tilbyde vores virksomheder og partnere overalt i verden et bredere udvalg af produkter og serviceydelser, er realiseringen af dette mål på den mest konkrete måde, og vi er begejstrede over at blive en del af Shift 4- teamet,” fortæller Igal Rotem, CEO for Finaro.
For yderligere information om denne nyerhvervelse, besøg venligst præsentationssektionen på Shift4s Investor Relations website her .
###
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220311005243/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
